4002:TADAWULMouwasat Medical Services Co. Analysis

Mouwasat Medical Services is trading at SAR 71.85, comfortably above its 20‑day (64.62) and 50‑day (66.46) SMAs and just above the 200‑day SMA (71.59), indicating short‑term momentum despite a technical label of “bearish.” The RSI of 66.9 suggests the stock is approaching overbought territory, while a bullish MACD histogram (+1.17) and increasing volume reinforce a near‑term upside bias toward the resistance level of 72.90. Valuation metrics are attractive: a trailing PE of 19x is well below the industry average of 26x, and the DCF‑derived fair value of 111.25 implies roughly 25% upside. The company delivers a solid 4.23% dividend yield with a payout ratio of 53%, strong ROE of 21.6%, and manageable leverage (debt‑to‑equity 27%).
The risk profile is tempered by a very low beta of 0.11 and a “Extreme Greed” sentiment index, but 30‑day volatility is high at nearly 39% and the max drawdown sits around -25.8%. Overall, the stock appears undervalued with a blend of growth and value characteristics, a sustainable dividend, and a long‑term upside thesis anchored by its DCF estimate.